Alonso J C, Lopez-Longo F J, Lampreave J L, González C M, Vegazo O, Carreño L, Almoguera I
Department of Nuclear Medicine, Hospital Universitario Gregorio Marañón, c/Maiquez 7, E-28009 Madrid, Spain.
Eur J Nucl Med. 1996 Mar;23(3):243-6. doi: 10.1007/BF00837621.
Abdominal scintigraphy with technetium-99m hexamethylpropylene amine oxime (99mTc-HMPAO)-labelled leucocytes is an excellent tool for evaluating disease extent and activity of intestinal lesions in patients with inflammatory bowel disease (IBD). In some cases of seronegative spondylarthropathies (SSp), IBD may remain subclinical. The aim of this study was to evaluate the presence of positive abdominal scintigraphy in patients with SSp and without clinical symptoms or signs of IBD. To this end we studied 32 patients with active SSp (European Spondylarthropathy Study Group 1991 criteria) without clinical evidence of IBD (eight had ankylosing spondylitis, four psoriatic arthritis, three reactive arthritis an 17 undifferentiated SSp) and 11 controls without SSp. All SSp and control patients received similar doses of non-steroidal anti-inflammatory drugs (NSAIDs). Abdominal scintigraphic images were obtained at 30 and 120 min after re-injection of 99mTc-HMPAO-labelled leucocytes. The 99mTc-HMPAO-labelled leucocyte scan was positive in 17 patients with SSp (53.1%) (six with ankylosing spondylitis, three with psoriatic arthritis, two with reactive arthritis and six with undifferentiated SSp). Fourteen patients scored from 2 to 4 on the intensity of uptake scale. The colon and terminal ileum were predominantly involved. Axial involvement was more frequent in patients with a positive scan than in patients with negative results (P<0.05) (64.7% vs 26.6%; odds ratio: 5). No control patient showed a positive scan. It is concluded that 99mTc-HMPAO-labelled leucocyte scan shows increased uptake among patients with SSp without evidence of IBD. These findings provide new evidence linking SSp with intestinal inflammation and suggest that in some cases a bowel-related process could contribute to the development of SSp. Long-term follow-up studies with more patients are necessary to evaluate the diagnostic and therapeutic implications of these results.
用锝-99m六甲基丙烯胺肟(99mTc-HMPAO)标记白细胞进行腹部闪烁扫描是评估炎症性肠病(IBD)患者肠道病变范围和活动度的极佳工具。在某些血清阴性脊柱关节病(SSp)病例中,IBD可能仍处于亚临床状态。本研究的目的是评估无IBD临床症状或体征的SSp患者腹部闪烁扫描阳性的情况。为此,我们研究了32例活动性SSp患者(符合1991年欧洲脊柱关节病研究组标准),这些患者无IBD的临床证据(8例为强直性脊柱炎,4例为银屑病关节炎,3例为反应性关节炎,17例为未分化SSp)以及11例无SSp的对照者。所有SSp患者和对照者接受了相似剂量的非甾体抗炎药(NSAIDs)。在重新注射99mTc-HMPAO标记的白细胞后30分钟和120分钟获得腹部闪烁扫描图像。17例SSp患者(53.1%)的99mTc-HMPAO标记白细胞扫描呈阳性(6例强直性脊柱炎患者,3例银屑病关节炎患者,2例反应性关节炎患者,6例未分化SSp患者)。14例患者的摄取强度评分为2至4分。主要累及结肠和回肠末端。扫描阳性患者的轴向受累比阴性结果患者更常见(P<0.05)(64.7%对26.6%;优势比:5)。对照者中无扫描呈阳性者。结论是锝-99m六甲基丙烯胺肟标记白细胞扫描显示无IBD证据的SSp患者摄取增加。这些发现为将SSp与肠道炎症联系起来提供了新证据,并表明在某些情况下,与肠道相关的过程可能促成SSp的发生。需要对更多患者进行长期随访研究以评估这些结果的诊断和治疗意义。